Navigation Links
Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
Date:3/10/2008

jection. Studies have shown these reactions occur in approximately one-third of patients, with 5% of the reactions categorized as severe. ANX-530 is designed to reduce the incidence and severity of these injection site reactions. Our formulation emulsifies vinorelbine into a homogeneous suspension of nanoparticles that is designed protect the venous endothelium during administration into a peripheral vein, thereby reducing irritation associated with administration of the drug.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk the FDA will determine that ANX-530 and Navelbine are not bioequivalent, including as a result of performing pharmacokinetic equivalence analysis based a patient population other than the population on which ADVENTRX based its analysis; the risk of investigator bias in reporting adverse events as a result of the study's open-label nature, including bias that increased the reporting of adverse events associated with Navelbine and/or that decreased the reporting of adverse events
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
2. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
3. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
4. Plurality Completes R&D of its HAL-256 Multicore Processor
5. First Complete Career Service for Life-Science Professionals
6. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
7. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
8. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
11. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
(Date:7/10/2014)... research may help in the fight against terrorism with ... quantities of explosives with the use of light and ... Sensors and Actuators B: Chemical , the researchers describe ... in concentrations as low as 6.3 ppm (parts per ... few minutes. , "Traditionally explosives detection has involved looking ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2
... Submission demonstrates progress of plant-derived insulin program, ... -, TSX symbol: SBS, CALGARY, July ... company developing a portfolio of therapeutic,proteins for metabolic ... an Investigational New Drug (IND) application for,safflower-produced recombinant ...
... ArunA Biomedical, Inc., the first,company to commercialize human ... that William T. Sharp has been named President,and ... leadership,responsibilities, Mr. Sharp has also been appointed to ... Steven Stice, PhD, who will,remain ArunA,s Chairman and ...
... MADISON Though bacteria are everywhere from the air we ... the vast majority are innocuous or even beneficial, and only ... microbial guest from an unwanted intruder? , Research from the ... but with the host. , A study appearing online this week ...
Cached Biology Technology:SemBioSys submits IND for safflower-produced insulin to U.S. FDA 2SemBioSys submits IND for safflower-produced insulin to U.S. FDA 3ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2Symbiotic microbes induce profound genetic changes in their hosts 2
(Date:7/11/2014)... City of Entiat on Tuesday, July 8, 2014. Despite ... to over 1,000 acres by evening. Three outbuildings were ... by the Washington Department of Natural Resources. The ... developing fire control strategies and tactics. Other cooperators include ... Natural Resources, (WA DNR), Bureau of Land Management, Chelan ...
(Date:7/11/2014)... the National Institute of Standards and Technology (NIST) ... more effectively, they often prove that necessity is ... case recently for M. Lorna De Leoz and ... specialization of glycomics. Glycomics is the study of ... are attached to proteins and lipids and influence ...
(Date:7/11/2014)... have explored two different ways that allow unprecedented ... the formation of oxygen molecules in photosynthesis. The ... journal Nature Communications . , "The new ... for water oxidation, which are key components for ... of solar energy in fuels like hydrogen, ethanol ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... IODP Arctic Coring Expedition (ACEX) is making news with new ... Nature, an article by several of the expedition scientists summarizes ... unusually wet, and ice-free up to the time the last ... atmosphere ?a period calculated to have occurred 55 million years ...
... designated Special Areas of Conservation throughout the UK, including ... pile driving. The frequency range of pile driving noise ... and avoid predators. This has the potential to affect ... Lactating females and young calves might be particularly vulnerable ...
... studies offer new evidence suggesting an alternative form of natural ... the blood in humans at levels determined to protect against ... in eight different forms. The primary vitamin E on drugstore ... of vitamin E surfacing as a potent neuroprotective agent in ...
Cached Biology News:Arctic coring expedition continues to yield new clues 2Dolphins at risk 2Natural vitamin E tocotrienol reaches blood at protective levels 2Natural vitamin E tocotrienol reaches blood at protective levels 3
...
... MMPs are a group of enzymes involved ... of matrix metalloproteinase family ten exist in ... membrane proteins. MT1-MMP, MT2-MMP, MT3-MMP also known ... C-terminal transmembrane domain anchoring them to the ...
...
... TURRAX Tube Disperser System from IKA Works is ... a cleaner, safer, and more efficient way to ... from 2 to 15 ml inside sealed tubes. ... one of 4 different tube types. Each tube ...
Biology Products: